Chlorobenzene

Chlorobenzene

SCHEMBL875663

CN(C)C.Clc1ccccc1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.73
CYP1A2 P05177 1/20 0.50
LMNA P02545 3/20 0.44
CYP2A6 P11509 1/20 0.44
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
GSK3B P49841 1/20 0.40
ORAI1 Q96D31 1/20 0.40
ORAI2 Q96SN7 1/20 0.40
ORAI3 Q9BRQ5 1/20 0.40
TRPV6 Q9H1D0 1/20 0.40
ALDH1A1 P00352 1/20 0.39
KCNN4 O15554 1/20 0.39
BCL2 P10415 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
ALOX12 P18054 1/20 0.37
ACHE P22303 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorobenzene SCHEMBL1987881 0.89
Chlorobenzene SCHEMBL10408107 0.86
Chlorobenzene SCHEMBL3930673 0.86
Chlorobenzene SCHEMBL1568605 0.86 TSHR (1.00) TSHRCYP1A2LMNACYP2A6CES2
Chlorobenzene SCHEMBL1331798 0.86
SCHEMBL24715429 0.86 TSHR (1.00) TSHRCYP1A2LMNACYP2A6CES2
Chlorobenzene SCHEMBL11220629 0.86 TSHR (1.00) TSHRCYP1A2LMNACYP2A6CES2
Chlorobenzene SCHEMBL2044 0.86
Chlorobenzene SCHEMBL2168046 0.86 TSHR (1.00) TSHRCYP1A2LMNACYP2A6CES2
Chlorobenzene SCHEMBL1330702 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023135499-A1 PROCESS FOR ROXADUSTAT USING NOVEL INTERMEDIATES OPTIMUS DRUGS PVT LTD (IN) 2023-07-20 WO claimed
US-8853439-B2 Processes for the preparation of lacosamide and intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2014-10-07 US claimed
EP-2534127-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN Laboratories Limited (IN) 2012-12-19 EP claimed
WO-2011099033-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES LIMITED (IN) 2011-08-18 WO claimed
CN-100386312-C Process for synthesizing 2,4-diamino benzene sulfonic acid and its salt SHANGHAI SHIJING INTERNAT TRAD (CN) 2008-05-07 CN claimed
CN-1900058-A Process for synthesizing 2,4-diamino benzene sulfonic acid and its salt SHIJING INTERNAT TRADE CO LTD (CN) 2007-01-24 CN claimed
EP-0388357-B1 Improved tinted contact lens and method of making the same CIBA GEIGY AG (CH) 1993-11-03 EP claimed
EP-0388357-A1 Improved tinted contact lens and method of making the same CIBA-GEIGY AG (CH) 1990-09-19 EP claimed
CN-119425402-A Composite filter film of nano cellulose fibril filter material and preparation method and application thereof 陕西铁路工程职业技术学院 2025-02-14 CN disclosed
WO-2023157209-A1 QUANTUM-DOT-CONTAINING COMPOSITION, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, AND METHOD FOR MANUFACTURING QUANTUM-DOT-CONTAINING COMPOSITION シャープディスプレイテクノロジー株式会社 2023-08-24 WO disclosed
WO-2023135499-A1 PROCESS FOR ROXADUSTAT USING NOVEL INTERMEDIATES OPTIMUS DRUGS PVT LTD (IN) 2023-07-20 WO disclosed
WO-2014205568-A1 PROCESSES FOR PREPARING AZIDATED COPOLYMERS LANXESS INC. (CA) 2014-12-31 WO disclosed
US-8907132-B2 Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide MSN LABORATORIES PRIVATE LIMITED (IN) 2014-12-09 US disclosed
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE MSN LABORATORIES PRIVATE LIMITED (IN) 2013-02-14 US disclosed
EP-0388357-B1 Improved tinted contact lens and method of making the same CIBA GEIGY AG (CH) 1993-11-03 EP disclosed
US-5098445-A Halotriazine reactive compounds for bonding with polymers for radiation resistance CIBA-GEIGY CORPORATION (US) 1992-03-24 US disclosed
US-5021068-A Tinted contact lens and method of manufacture thereof: reactive dye and quaternary phosphonium salt CIBA-GEIGY CORPORATION (US) 1991-06-04 US disclosed
EP-0388357-A1 Improved tinted contact lens and method of making the same CIBA-GEIGY AG (CH) 1990-09-19 EP disclosed
US-4490473-A Labeled antibodies and methods PANAB (US) 1984-12-25 US disclosed
US-3982005-A ANALGESICS BOEHRINGER INGELHEIM GMBH (DT) 1976-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130041180-A1 PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE AMY1A, PTMA, NAAA TSHR 1758/4885CYP1A2 9/4885LMNA 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.